Ignite Creation Date:
2025-12-24 @ 4:39 PM
Ignite Modification Date:
2026-01-25 @ 2:55 AM
Study NCT ID:
NCT04198766
Status:
ACTIVE_NOT_RECRUITING
Last Update Posted:
2025-12-18
First Post:
2019-12-11
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)
Sponsor:
Inhibrx Biosciences, Inc
Organization:
Conditions & Keywords Data
Conditions:
Keywords:
Keywords
| Keyword Brief | Keyword Text | View |
|---|---|---|
| None | Phase 1 and Phase 2 | View |
| None | Phase 1 and Phase 2 Clinical Trial | View |
| None | Solid Tumors | View |
| None | Head and Neck Cancer | View |
| None | Lung Cancer | View |
| None | Non-Small Cell Lung Cancer | View |
| None | OX40 receptor agonist | View |
| None | PD-L1 positive | View |
| None | Pembrolizumab | View |
| None | Keytruda | View |
| None | Chemotherapy | View |
| None | Immunotherapy | View |
| None | HNSCC | View |
| None | Oropharyngeal cancer | View |
| None | Hypopharyngeal cancer | View |
| None | Oral cancer | View |
| None | INBRX-106 | View |
| None | Neoplasms, Glandular and Epithelial | View |
| None | Neoplasms by Histologic Type | View |
| None | Neoplasms | View |
| None | Neoplasms, Squamous Cell | View |
| None | Head and Neck Neoplasms | View |
| None | Neoplasms by Site | View |
| None | Carcinoma | View |
| None | Carcinoma, Squamous Cell | View |
| None | Molecular Mechanisms of Pharmacological Action | View |
| None | Antineoplastic Agents, Immunological | View |
| None | Antineoplastic Agents | View |
| None | Squamous Cell Carcinoma of Head and Neck | View |
| None | NSCLC | View |